Ingrid Glimelius
Affiliated to Research
E-mail: ingrid.glimelius@ki.se
Visiting address: Maria Aspmans gata 30A, 17164 Solna
Postal address: K2 Medicin, Solna, K2 KEP Ekström Smedby, 171 77 Stockholm
About me
- I am a professor in Oncology at Uppsala University. I am also a senior consultant in oncology. I working mainly with
lymphoma- and testicular cancer patients. I am affiliated to both Karolinska Institutet and Uppsala University,
https://www.igp.uu.se/research/cancer-precision-medicine/ingrid-glimelius/.
I have been collaborating with Karin E Smedby and been affiliated to the Cancer
Epidemiology group at the Division of Clinical Epidemiology, Karolinska
Institutet since long. In addition to my clinical work I perform clinical
phase I-III studies and epidemiological studies. I supervise PHD-students and
post docs and I teach both medical students and senior physicians. I have
been awarded Senior Clinical Investigator Cancer Award from the Swedish
Cancer Society in spring 2019.
I have research collaborations with both Uppsala University, Ahlborg
University, Mayo Clinic in the US. The Nordic lymphoma group.
I participate and include patients in clinical trial, phase I, phase II and
phase III, mainly within the field of lymphoma and particularly mantle cell
lymphoma. We introduce novel targeted drugs, explore immunotherapies and
implement new disease monitoring tools.
MD, Uppsala University 2001
PHD, Uppsala University 2009, /Hodgkin lymphoma – an interplay between
tumour cell and microenvironment/
MD, specialist Internal Medicine 2011
MD, specialist Oncology 2013
Associate Professor in Oncology 2016
Good Clinical Practice, Investigator Site Personnel ICH-GCP 2017
Senior consultant, Oncology 2019
Senior Clinical Investigator Award, the Swedish Cancer Society 2019-2025
Senior lecturer since 2021
Professor Uppsala University 2023
Research
- My primary research interest is in malignant lymphomas, with a specific
focus on Hodgkin lymphoma and Mantle cell lymphoma. In addition, I have an
interest in Ovarian and Testicular cancer.
*Mantle cell lymphoma (MCL)* is one of the lymphoma subtype that with
combination chemotherapy still has a poor survival, although prognostic
heterogeneity exists. Using epidemiological “real-world data” I
investigate treatment selection and the prognostic implication of associated
diseases. I am also national principal investigator for the *ENRICH*-trial: A
randomized phase III study for elderly MCL patients with randomization
between Rituximab-Ibrutinib AND Rituximab-chemotherapy (Bendamustine or CHOP)
with the aim to test if a chemotherapy free concept can improve survival. I
am also local PI for the *VALERIA* trial in Uppsala testing
Lenalidomide-Venetoclax and Rituximab for relapsed/refractory mantle cell
lymphoma patients. We started in year 2022 the *ALTAMIRA* trial that
investigates a disease monitoring approch with minimal residual disease
monitoring for elderly mantle cell lymphoma patients treated with
acalabrutinib and rituximab.
In addition, my research interests are in young cancer patients, with a
specific focus on survivorship, particularly childbearing potential and
long-term prognosis for *Hodgkin lymphoma patients, other lymphoma subtypes
and testicular cancer*. I describe late adverse effects from both
chemotherapy and radiotherapy. We have in collaboration with other researcher
and specifically Caroline Weibull (https://ki.se/people/cardie [1]) published
a series of publications regarding childbearing potential in Hodgkin lymphoma
survivors (please see below).
I also study other lymphatic malignancies, *testicular cancer* and *ovarian
cancer* both regarding aetiology, prognosis and late-effects from treatment.
[1] https://ki.se/people/cardie
Teaching
- Teacher Medical School, Oncology, Uppsala University since year 2010-
Teacher research school in Epidemiology, Karolinska Institutet 2013-2014
Steering committee National Research School in Oncology, NATION, since 2017-
Examiner for project-works in Medical School, Uppsala University since 2017-
Articles
- Article: EJHAEM. 2024;5(5):998-1004
- Article: BLOOD. 2024;144(9):1001-1009
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2024;205(2):542-551
- Article: CANCER CAUSES AND CONTROL. 2024;35(8):1101-1109
- Article: ACTA ONCOLOGICA. 2024;63:563-572
- Article: HEMASPHERE. 2024;8(7):e121
- Article: BJU INTERNATIONAL. 2024;133(6):717-724
- Article: CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY. 2024;46:100785
- Article: CANCER CAUSES AND CONTROL. 2024;35(5):741-747
- Article: HAEMATOLOGICA. 2024;109(4):1171-1183
- Article: JCO CLINICAL CANCER INFORMATICS. 2024;8:e2300255
- Article: JOURNAL OF CANCER SURVIVORSHIP. 2024;:1-11
- Article: BLOOD ADVANCES. 2024;8(2):407-415
- Article: INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 2023;52(6):1826-1835
- Article: ACTA ONCOLOGICA. 2023;62(12):1707-1715
- Article: EUROPEAN JOURNAL OF CANCER. 2023;195:113403
- Journal article: BLOOD. 2023;142(Supplement 1):1729
- Article: BLOOD ADVANCES. 2023;7(18):5304-5313
- Article: BJU INTERNATIONAL. 2023;132(3):329-336
- Article: INTERNATIONAL JOURNAL OF CANCER. 2023;153(4):723-731
- Article: HEMASPHERE. 2023;7(8):e928
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2023;202(4):785-795
- Article: BRITISH JOURNAL OF CANCER. 2023;128(12):2261-2269
- Journal article: INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 2023;52(3):966
- Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(16_suppl):5008
- Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):477-478
- Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(16_suppl):tps7595
- Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):476-477
- Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):369-370
- Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:475-476
- Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:472-474
- Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:471-472
- Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:746-748
- Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:474-475
- Article: CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION. 2023;32(5):687-696
- Article: INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 2023;52(2):450-465
- Article: BLOOD ADVANCES. 2023;7(5):866-874
- Article: AMERICAN JOURNAL OF EPIDEMIOLOGY. 2023;192(1):70-83
- Journal article: HEMASPHERE. 2022;6(Suppl ):37-38T082: AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients
- Journal article: HEMASPHERE. 2022;6(Suppl ):37P081: Treatment-related circulatory diseases and mortality in Hodgkin lymphoma patients using multi-state modelling and relative survival
- Journal article: HEMASPHERE. 2022;6(Suppl ):30T065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
- Journal article: HEMASPHERE. 2022;6(Suppl ):44P096: Polymorphisms in SETD7 may predispose the risk of developing late cardiac side effects after radiotherapy including the mediastinum in Hodgkin’ s lymphoma.
- Journal article: HEMASPHERE. 2022;6(Suppl ):42P091: Early analysis of the PRO-Hodgkin study: Clinical investigation of pencil beam scanning proton treatment in Hodgkin lymphoma patients
- Journal article: ANNALS OF ONCOLOGY. 2022;33:s1197-s1198
- Journal article: HEMASPHERE. 2022;6:103-104
- Journal article: HEMASPHERE. 2022;6(Suppl):983-984
- Journal article: CANCER RESEARCH. 2022;82(12_Supplement):2026
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2022;197(5):580-589
- Article: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(13):1487-1496
- Article: INTERNATIONAL JOURNAL OF CANCER. 2022;150(5):773-781
- Article: BLOOD CANCER JOURNAL. 2022;12(1):16
- Article: ACTA ONCOLOGICA. 2021;60(11):1459-1465
- Article: JOURNAL OF CLINICAL ONCOLOGY. 2021;39(31):3463-3472
- Article: EJHAEM. 2021;2(3):400-412
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;193(5):906-914
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;193(3):520-531
- Article: BLOOD ADVANCES. 2021;5(6):1671-1681
- Article: BLOOD ADVANCES. 2021;5(6):1638-1647
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(3):551-559
- Article: THE LANCET DIABETES AND ENDOCRINOLOGY. 2021;9(2):94-105
- Article: HEMASPHERE. 2021;5(1):e510
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;191(5):796-805
- Article: ACTA ONCOLOGICA. 2020;59(8):949-958
- Article: BRITISH JOURNAL OF CANCER. 2020;123(1):161-166
- Article: EJHAEM. 2020;1(1):199-207
- Article: EUROPEAN UROLOGY ONCOLOGY. 2020;3(3):382-389
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(6):1083-1092
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(1):106-116
- Article: INTERNATIONAL JOURNAL OF CANCER. 2020;146(6):1523-1531
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;188(5):685-691
- Article: IMMUNOBIOLOGY. 2020;225(1):151872
- Article: INTERNATIONAL JOURNAL OF CANCER. 2019;145(5):1200-1208
- Article: CANCER MEDICINE. 2019;8(10):4918-4927
- Journal article: HEMASPHERE. 2019;3(S1):141-142
- Journal article: HEMATOLOGICAL ONCOLOGY. 2019;37(S2):242
- Article: PLOS MEDICINE. 2019;16(6):e1002816
- Article: JOURNAL OF INTERNAL MEDICINE. 2019;285(4):455-468
- Article: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(9):703-713
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2019;184(2):192-201
- Article: INTERNATIONAL JOURNAL OF CANCER. 2018;143(8):1904-1913
- Article: INTERNATIONAL JOURNAL OF CANCER. 2018;143(8):1858-1867
- Article: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(26):2718-2725
- Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2018;101(1):106-114
- Article: JOURNAL OF INTERNAL MEDICINE. 2018;283(5):430-445
- Article: RADIOTHERAPY AND ONCOLOGY. 2018;126(3):424-430
- Article: ACTA ONCOLOGICA. 2018;57(2):276-282
- Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2018;100(1):88-97
- Article: PLOS ONE. 2018;13(9):e0204870
- Article: AMERICAN JOURNAL OF EPIDEMIOLOGY. 2017;186(10):1159-1167
- Article: BLOOD ADVANCES. 2017;1(18):1427-1439
- Journal article: HEMATOLOGICAL ONCOLOGY. 2017;35(S2):100-101
- Journal article: HEMATOLOGICAL ONCOLOGY. 2017;35(S2):172-173
- Article: AMERICAN JOURNAL OF EPIDEMIOLOGY. 2017;185(8):681-687
- Article: AMERICAN JOURNAL OF HEMATOLOGY. 2017;92(3):251-258
- Article: BRITISH JOURNAL OF CANCER. 2016;115(11):1416-1420
- Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2016;97(5):430-438
- Article: LEUKEMIA AND LYMPHOMA. 2016;57(10):2351-2358
- Article: JOURNAL OF CANCER SURVIVORSHIP. 2016;10(3):514-523
- Article: CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION. 2016;25(6):987-994
- Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2016;51(5):583-589
- Article: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(4):337-344
- Article: AMERICAN JOURNAL OF HEMATOLOGY. 2015;90(12):1128-1134
- Article: JOURNAL OF CANCER SURVIVORSHIP. 2015;9(4):599-609
- Article: CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION. 2015;24(12):1838-1843
- Article: ACTA ONCOLOGICA. 2015;54(10):1770-1780
- Article: AMERICAN JOURNAL OF EPIDEMIOLOGY. 2015;182(7):624-632
- Article: BRITISH JOURNAL OF SURGERY. 2015;102(11):1426-1432
- Article: BLOOD. 2013;122(20):3492-3499
- Article: HISTOPATHOLOGY. 2012;61(1):26-32
- Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2011;87(3):208-216
- Article: EXPERIMENTAL HEMATOLOGY. 2011;39(8):850-858
- Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2008;67(1):53-56
- Article: HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA. 2007;21(5):805-823
- Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2006;76(4):278-283
- Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2003;71(5):327-333
- Article: JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA). 2003;290(4):465-475
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2002;119(1):122-124
- Article: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2002;94(3):182-192
- Show more
All other publications
- Review: JOURNAL OF INTERNAL MEDICINE. 2024;295(6):715-734
- Editorial comment: ANNALS OF ONCOLOGY. 2024;35(3):245-247
- Review: FRONTIERS IN IMMUNOLOGY. 2024;15:1373269
- Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(16)
- Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(16)
- Conference publication: AMERICAN JOURNAL OF HEMATOLOGY. 2023;98:S51-S52
- Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(16)
- Conference publication: CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2023;23:S457-S458
- Conference publication: JOURNAL OF UROLOGY. 2023;209:E451
- Conference publication: BLOOD. 2022;140:9411-9412
- Conference publication: BLOOD. 2022;140:1079-1081
- Conference publication: BLOOD. 2022;140:184-185
- Conference publication: ANNALS OF ONCOLOGY. 2022;33(7):S777
- Editorial comment: BRITISH JOURNAL OF HAEMATOLOGY. 2022;198(1):11-13
- Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2022;97(7):E255-E257
- Conference publication: CANCER RESEARCH. 2022;82(12)
- Conference publication: JOURNAL OF UROLOGY. 2022;207(5):E845
- Conference publication: ANNALS OF ONCOLOGY. 2021;32:S748-S749
- Letter: HAEMATOLOGICA. 2021;106(9):2502-2506
- Conference publication: BLOOD. 2020;136:3-4
- Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2020;190(4):e245-e248
- Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2020;95(2):E36-E38
- Conference publication: JOURNAL OF UROLOGY. 2020;203:E384
- Conference publication: AMERICAN JOURNAL OF HEMATOLOGY. 2020;95:S14-S15
- Conference publication: BLOOD. 2019;134:2841
- Conference publication: BLOOD. 2019;134:4572
- Review: LEUKEMIA AND LYMPHOMA. 2019;60(13):3116-3131
- Conference publication: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2019;29:A148-A149
- Preprint: SSRN ELECTRONIC JOURNAL. 2019
- Conference publication: BLOOD. 2018;132:930
- Conference publication: BLOOD. 2018;132:3120
- Conference publication: BLOOD. 2018;132:2891
- Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2017;35:tps4593
- Review: JOURNAL OF INTERNAL MEDICINE. 2017;281(3):247-260
- Conference publication: HAEMATOLOGICA. 2016;101:36
- Conference publication: HAEMATOLOGICA. 2016;101:3
- Conference publication: HAEMATOLOGICA. 2016;101:1-2
- Conference publication: HAEMATOLOGICA. 2016;101:64-65
- Conference publication: HAEMATOLOGICA. 2016;101:22
- Corrigendum: JOURNAL OF CANCER SURVIVORSHIP. 2015;9(4):610-611
- Letter: LEUKEMIA. 2005;19(12):2360-2362
- Show more
Employments
- Affiliated to Research, Department of Medicine, Karolinska Institutet, 2023-2026
Supervisor
- Caroline Weibull, Survivorship in Hodgkin lymphoma : childbearing and treatment-related disease, https://openarchive.ki.se/xmlui/handle/10616/46467, 2014